John T. Vaage

Professor II

University of Oslo

Norway

Research Interests

Explore related searches

Professors in Norway Professors in Immunology Immunology professors in Norway

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

John T. Vaage is a Professor II at the University of Oslo, Norway. His research focuses on immunology, particularly related to SARS-CoV-2, vaccine responses, and immune responses in patients with pre-existing conditions. He has published extensively on vaccine efficacy, hybrid immunity, and the antibody landscape in various populations, contributing valuable insights into public health and immunization strategies.

Articles (11)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (7)

Knut E. A. Lundin

University of Oslo

NORWAY

View details

Tore Kristian Kvien

Professor

University of Oslo

NORWAY

View details

Bente Halvorsen

Oslo University Hospital

NORWAY

View details

Linda Elise Couëssurel Wüsthoff

Associate Professor

University of Oslo

NORWAY

View details

Siri Mjaaland

Senior Scientist/Professor

Norwegian Institute of Public Health

NORWAY

View details

Andreas Lind

Senior Medical Officer, Head of Unit

Oslo University Hospital

NORWAY

View details

Ludvig A Munthe

professor

University of Oslo

NORWAY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John T. Vaage

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

An intranasal subunit vaccine induces protective systemic and mucosal antibody immunity against respiratory viruses in mouse models.

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Seroprevalence of SARS-CoV-2 and humoral immune responses to COVID-19 mRNA vaccines among people who use drugs - in the light of tailored mitigating strategies

People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study.

Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infections

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults

Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease.

Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.

Immune responses to SARS-CoV-2 vaccines in celiac disease

Collaborators (7)

Knut E. A. Lundin

Tore Kristian Kvien

Bente Halvorsen

Linda Elise Couëssurel Wüsthoff

Siri Mjaaland

Andreas Lind

Ludvig A Munthe

Make your next move.